Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
US Myeloma Immunotherapy Consortium data show median PFS with teclistamab of 1.4 mos in true-EMD, 6.51 mos with paraskeletal plasmacytomas, 8.95 mos in no soft tissue plasmacytomas; median OS 9.54, 13.1 months, and not reached.”
Title: The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Authors: Aimaz Afrough, Danai Dima, Beatrice Razzo, Utkarsh Goel, Aishwarya Sannareddy, Oren Pasvolsky, Mariola A. Vazquez-Martinez, Christopher J. Ferreri, Rahul Banerjee, Jack Khouri, James A. Davis, Mahmoud R. Gaballa, Alex Lieberman-Cribbin, Masooma S. Rana, Kelley Julian, Faiz Anwer, Leyla Shune, Shaun DeJarnette, Ariel F. Grajales-Cruz, Evguenia Ouchveridze, Gabriel De Avila, Sandra P. Susanibar-Adaniya, Andrew J. Portuguese, Daniel Schrum, Erin Eberwein, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Joseph P. McGuirk, Adriana Rossi, Megan M. Herr, Omar Castaneda, Frederick L. Locke, Shahzad Raza, Yi Lin, Shebli Atrash, Douglas W. Sborov, Peter M. Voorhees, Shambavi Richard, Alfred L. Garfall, Surbhi Sidana, Krina K. Patel, Doris K. Hansen, Andrew J. Cowan, Larry D. Anderson Jr., Hans C. Lee
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
